Company: BLLN
Filing Date: 2025-12-10
Form Type: 10-Q
Source: 0001628280-25-056321
Chunk: 350

Company: BillionToOne, Inc.
Filing Date: 2025-12-10
Form: 10-Q
Item: Part I, Item 8
Chunk 350
---
 regulatory, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether the achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied to the contract price such that it is probable a significant cumulative reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price. The Company recognizes revenue for the single performance obligation for the J&J partnership agreements over the period the services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to the total expected costs as a measure of progress. The Company assesses the changes to the total expected cost estimates in determining the revenue recognition for each reporting period.The Company applies the practical expedient not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. As of September 30, 2025, the Company’s remaining performance obligations beyond one year were approximately $4.7 million.

12

Table of ContentsBillionToOne, IncNotes to Unaudited Interim Financial Statements

Disaggregation of revenueThe following table presents disaggregation of revenue by Prenatal, Oncology and Clinical trial support and other services for the three and nine months ended September 30, 2025 and 2024 (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Prenatal$74,071 $36,601 $191,001 $102,680 Oncology8,691 1,138 15,814 1,851 Clinical trial support and other services761 680 2,244 2,974 Total revenues$83,523  $38,419 $209,059 $107,505 Substantially all revenues recognized for the three and nine months ended September 30, 2025 and 2024 were generated in the United States.Deferred revenueDeferred revenue, which is a contract liability, consists of billings or cash received for services in advance of revenue recognition and is recognized as revenue when all the Company’s revenue recognition criteria are met. As of September 30,